IP Library Granted Patent US 11,299,491
Granted Patent B2
US 11,299,491 · App. 16/685,841 · Granted Apr 12, 2022

Synthesis of key intermediate of KRAS G12C inhibitor compound

Inventors: Andrew Thomas Parsons (Thousand Oaks, CA); Brian McNeil Cochran (Thousand Oaks, CA); William Powazinik, IV (Thousand Oaks, CA); Marc Anthony Caporini (Thousand Oaks, CA)
Assignee: AMGEN INC.
C07D471/04C07C69/76C07C309/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,299,491
App. No.
16/685,841
Filed
Nov 15, 2019
Granted
Apr 12, 2022
Kind
B2
Art Unit
1629
USPC
514/252.15
Abstract

The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure useful for the synthesis of compounds that target KRAS G12C mutations, such as

Claims (1)

1. A compound, wherein the compound is:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2020
From: PARSONS, ANDREW THOMAS; COCHRAN, BRIAN MCNEIL; POWAZINIK, WILLIAM, IV; CAPORINI, MARC ANTHONY
To: AMGEN INC.
Reel/Frame 053017/0393 →
Continuity (2)
Provisional Application 62768802 · Nov 16, 2018
Related Publication 20200216446A1 · Jul 9, 2020
Cited By (16)
US 12,280,056 US 12,391,689 US 12,398,133 US 12,415,806 US 12,421,234 US 12,440,491 US 12,441,729 US 12,466,840 US 12,479,834 US 12,582,657 US 12,583,854 US 12,630,559 US 12,643,885 US 12,673,041 US 12,692,266 US 12,702,658